Flagship Pioneering has officially launched Terrana Biosciences, a company focused on deploying RNA based tools to enhance agricultural productivity and crop resilience. With an initial investment of US$ 50 million, Flagship’s support marks the culmination of four years of platform development. The company will use this funding to scale its operations and bring to market its first suite of crop protection and yield enhancing products.
Terrana is developing solutions that do not alter the plant genome but instead leverage native RNA mechanisms within plants. These products are designed for flexible deployment at any stage of a plant’s lifecycle, aiming to create a continuous, adaptive pipeline of applications that respond to environmental variability with greater speed and lower cost than traditional agricultural methods.
Utilising Plant Native RNA Mechanisms to Influence Traits
At the core of Terrana’s approach is the utilization of self replicating RNAs that exist naturally within plants. These RNAs play a role in regulating a wide range of biological functions, including growth, stress response and development. Terrana’s technology builds upon this biological foundation to design novel functional traits that communicate with plants using their existing molecular language.
Through advanced AI driven design systems and computational modelling, the company has constructed a large library of functional RNAs. This library enables the design and assembly of crop traits with a high degree of precision, adaptability, and efficiency. The platform has already resulted in the creation of three distinct technology classes and has demonstrated proof of concept in tomatoes, corn and soy. Terrana is currently advancing a product pipeline comprising more than 15 candidates targeting both specialty and row crops.
“At Flagship Pioneering, we build groundbreaking platforms that address the world’s most pressing challenges. With Terrana, we are bringing an entirely new dimension of innovation to agriculture through similar RNA technology that we pioneered in human health. This approach will empower farmers with precise, adaptive solutions to combat threats to crops in fields and orchards and enhance resiliency, sustainability and productivity in the global food system.”
Agricultural Tools Designed for Real Time Environmental Adaptation
Terrana’s product portfolio is designed to give farmers more flexibility and control throughout the growing season. Unlike traditional crop protection tools that must be applied at specific growth stages, Terrana’s RNA based solutions can be administered at any point in the crop lifecycle, from seed to post harvest. This temporal flexibility allows for more dynamic responses to real time threats such as disease outbreaks, pest infestations or sudden weather events.
These tools also aim to minimize environmental impact. The platform’s outputs are engineered for properties such as amplification, mobility within the plant, environmental stability and heritability across plant generations. By avoiding the limitations and environmental drawbacks of conventional inputs, Terrana aims to offer a next generation approach tailored to both short term and long term agricultural demands.
“RNA-based technology has delivered lifesaving advancements in human health. We are now applying this same approach to reimagine what’s possible for agriculture. Using the language of nature, we can give plants new instructions, yielding adaptable solutions rooted directly in the plant’s natural physiology. Our approach opens a new world of possibilities in annual and perennial crops for the benefit of farmers, people and the planet.”
Reframing the Decision Making Timeline for Farmers
The company’s approach is intended to shift the timeline and basis for agricultural decision making. Farmers typically make costly upfront decisions regarding seeds, fertilizers and crop protection based on historical data and seasonal projections. However, increasing climate unpredictability and fast evolving biotic threats have made these assumptions less reliable. Terrana’s platform is structured to offer flexible tools that farmers can deploy in response to in season developments.
Also read: Eeki Raises $7M to Install Gen 3 Aeroponic Chambers
The company argues that current R&D cycles in agriculture are too slow and expensive to keep up with the pace of global changes, and its technology aims to close that gap. By enabling trait activation and modulation throughout the plant lifecycle, Terrana provides tools that can help farmers remain agile amid market volatility, weather disruptions and emerging pest pressures.
Leadership Team and Strategic Governance
Terrana Biosciences is led by Ryan Rapp, who serves as Chief Executive Officer and Origination Partner at Flagship Pioneering. The leadership team also includes Matthew Lingard as Chief Technology Officer, Folashade Sabitu as Head of Regulatory, and Ramtin Ahmadi as Vice President of Strategy and Operations.
The company’s board of directors includes Ignacio Martinez, who is also Co-Founder and Executive Chairman of Terrana and a General Partner at Flagship. Other board members include Hugh Grant, Amy O’Shea (CEO of Invaio and Flagship CEO-Partner), and André Andonian, who serves as Flagship’s Chair of Asia Pacific and Strategic Advisor. Together, the leadership and board bring experience across agriculture, biotechnology, regulation and global corporate strategy.
Bringing Human Health RNA Insights into Agriculture
The conceptual underpinnings of Terrana’s platform are informed by the progress of RNA based technologies in human health. According to the company, similar methods are now being applied to plants, using their own molecular processes to encode new instructions for traits. This cross domain application of RNA insights is intended to open new possibilities in both annual and perennial cropping systems.
By focusing on RNA’s potential in trait expression and control, Terrana positions itself to offer farmers tools that are embedded in plant biology and adaptable to environmental realities, without relying on genetic modification or slow R&D pipelines.